Working through the Global Fund Advocates Network (GFAN), tuberculosis (TB) advocates are looking to strategically advance efforts to combat the disease and take advantage of several key international meetings over the coming 15 months.
Two high-profile initiatives were launched late last year, each designed to shore up the response to the global tuberculosis epidemic.
The World Health Organization has issued new recommendations for the treatment of multi-drug-resistant TB, involving the use of a regimen that is shorter and cheaper compared to what is currently being used.
In this fast-paced world, it is easy sometimes to forget the individual stories of those affected by the three diseases. These personal stories resonate with all of us as global citizens. They are critical in highlighting the significance of the work of Global Fund–supported programs, bringing true meaning and value to the $13 billion replenishment target.
Somalia has a major burden of multi-drug-resistant TB (MDR-TB), rivalling that of the most-affected countries in Asia. According to World Vision International Somalia (WVI-S), principal recipient (PR) for the Global Fund’s TB grants in Somalia, the first shipment of medicines to treat MDR-TB is expected to arrive this month.
The Grants Renewal Panel says that overall performance of a single-stream-of-funding TB grant in Nepal has been high and that there is an opportunity for scale-up in the next implementation period.
TB mortality has decreased significantly since 2000 and treatment success rates have shown steady improvement. More than half of the countries that have received Global Fund support are on track to meet the international targets for case detection, treatment success, and TB disease incidence. However, multi-drug-resistant TB (MDR-TB) remains a critical threat.